Cover Image
市場調查報告書

性病相關的各種合作契約:契約條件·協定內容

Global Sexual Health Partnering 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 250311
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
性病相關的各種合作契約:契約條件·協定內容 Global Sexual Health Partnering 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告提供全球各國近幾年性病相關的各種合作契約趨勢分析,提供整體交易數量·金額趨勢和結構,大企業趨勢,交易種類/開發階段/不同技術及各適應症詳細趨勢等調查,並將結果概述為以下內容。

執行摘要

第1章 簡介

第2章 性病相關的各種契約趨勢

  • 簡介
  • 過去數年性病相關的各種合作趨勢
  • 大型製藥企業的性病相關契約締結活動
  • 並不積極締結性病相關契約的大型製藥企業
  • 性病相關的各種合作:各類型交易
  • 性病相關的各種合作:各產業
  • 性病相關的各種合作:各開發階段
  • 按性病相關的各種合作:技術類型
  • 性病相關的各種合作:各適應症
  • 性病相關合作的平均契約條件
    • 付款總額
    • 預付款
    • 階段性付款
    • 提成率

第3章 性病相關的代表性交易

  • 簡介
  • 主要交易:各契約金額
  • 與大型製藥企業相關,具代表性的交易

第4章 大型製藥企業的性病相關契約

  • 簡介
  • 大型製藥企業合作交易的有效利用方法
  • 企業簡介
    • Abbott
    • Bayer
    • GlaxoSmithKline
    • Menarini
    • Merck & Co
    • Mylan
    • Pfizer
    • Roche
    • Teva
    • Valeant
    • Warner Chilcott
    • Watson

第5章 性病相關合作交易的一覽

  • 簡介
  • 交易的各類型
    • 資產購買
    • 共同研究開發(R&D)
    • 開發
    • 流通
    • 合資企業
    • 許可證
    • 製造
    • 行銷
    • 材料移動
    • 調停
    • 輔助的契約(輔助契約)
    • 契約結束
  • 各開發階段
    • 定式化
    • 市售
    • 階段II
    • 階段III
    • 前臨床
    • 法規
  • 技術類型
    • 生物學的化合物
    • 設備
    • 診斷手法
    • 藥物遞送
    • 小分子

第6章 性病相關的交易趨勢:各適應症

  • 簡介
  • 各適應症的交易數量
    • 性病
    • 細菌性陰道炎
    • 黴菌性口炎念珠菌
    • 避孕
    • 男性勃起障礙(ED)
    • 性功能不全
    • 性感染疾病(STI)
    • 披衣菌感染
    • 尖頭濕疣
    • 淋病
    • 帶狀皰疹(皰疹)
    • 梅毒
    • 毛滴蟲屬症

第7章 合作機會

  • 線上·合作夥伴
  • 合作夥伴·活動
  • 相關資料

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2212

The ‘Global Sexual Health Partnering 2010-2016: Deal trends, players and financials report’ provides comprehensive understanding and unprecedented access to the sexual health partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Sexual Health Partnering 2010 to 2016’ provides the full collection of Sexual Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Sexual Health partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Sexual Health partnering agreement structure
  • Sexual Health partnering contract documents
  • Top Sexual Health deals by value
  • Most active Sexual Health dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Sexual Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Sexual Health deals.

The report presents financial deal terms values for Sexual Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Sexual Health dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Sexual Health dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Sexual Health deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Sexual Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Sexual Health deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Sexual Health partnering deals by specific Sexual Health target announced since 2010. The chapter is organized by specific Sexual Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Sexual Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Sexual Health partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Sexual Health technologies and products.

Report scope

‘Global Sexual Health Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Sexual Health trends and structure of deals entered into by leading companies worldwide.

‘Global Sexual Health Partnering 2010 to 2016’ includes:

  • Trends in Sexual Health dealmaking in the biopharma industry since 2010
  • Analysis of Sexual Health deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Sexual Health deal contract documents
  • Comprehensive access to over 3500 Sexual Health deal records
  • The leading Sexual Health deals by value since 2010
  • Most active Sexual Health dealmakers since 2010

The report includes deals for the following indications: Bacterial vaginosis, Candida albicans (Thrush), Contraception, Erectile dysfunction, Sexual dysfunction, Sexually transmitted disease (STI), Chlamydia, Genital warts, Gonorrhea, Herpes, Syphilis, Trichomoniasis, plus other sexual health indications.

In ‘Global Sexual Health Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Sexual Health Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 100 sexual health deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Sexual Health Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Sexual Health deal trends since 2010
  • Access Sexual Health deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Sexual Health partner companies
  • Comprehensive access to over 750 links to actual Sexual Health deals entered into by the world's biopharma companies
  • Indepth review of Sexual Health deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Sexual Health opportunities
  • Uncover companies actively partnering Sexual Health opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Sexual Health dealmaking

  • 2.1. Introduction
  • 2.2. Sexual Health partnering over the years
  • 2.3. Sexual Health partnering by deal type
  • 2.4. Sexual Health partnering by industry sector
  • 2.5. Sexual Health partnering by stage of development
  • 2.6. Sexual Health partnering by technology type
  • 2.7. Sexual Health partnering by therapeutic indication

Chapter 3 -Financial deal terms for Sexual Health partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Sexual Health partnering
  • 3.3. Sexual Health partnering headline values
  • 3.4. Sexual Health deal upfront payments
  • 3.5. Sexual Health deal milestone payments
  • 3.6. Sexual Health royalty rates

Chapter 4 - Leading Sexual Health deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Sexual Health partnering
  • 4.3. List of most active dealmakers in Sexual Health
  • 4.4. Top Sexual Health deals by value

Chapter 5 - Sexual Health contract document directory

  • 5.1. Introduction
  • 5.2. Sexual Health partnering deals where contract document available

Chapter 6 - Sexual Health dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Sexual Health therapeutic target

Appendices

  • Appendix 1 - Directory of Sexual Health deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Sexual Health deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Sexual Health deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Sexual Health deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Sexual Health partnering since 2010
  • Figure 2: Sexual Health partnering by deal type since 2010
  • Figure 3: Sexual Health partnering by industry sector since 2010
  • Figure 4: Sexual Health partnering by stage of development since 2010
  • Figure 5: Sexual Health partnering by technology type since 2010
  • Figure 6: Sexual Health partnering by indication since 2010
  • Figure 7: Sexual Health deals with a headline value
  • Figure 8: Sexual Health deals with upfront payment values
  • Figure 9: Sexual Health deals with milestone payment
  • Figure 10: Sexual Health deals with royalty rates
  • Figure 11: Active Sexual Health dealmaking activity- 2010 to 2016
  • Figure 12: Top Sexual Health deals by value since 2010
Back to Top